Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Eggenhuizen

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Biomedicines|March 28, 2024
The Influence of Cross-Reactive T Cells in COVID-19Peter J Eggenhuizen, Joshua D Ooi
Immunology and Cell Biology|December 5, 2020
Antigen-driven CD4<sup>+</sup> T-cell anergy: a pathway to peripheral T regulatory cellsPeter J Eggenhuizen, Boaz H Ng, Joshua D Ooi
International Journal of Molecular Sciences|September 26, 2020
Treg Enhancing Therapies to Treat Autoimmune DiseasesPeter J Eggenhuizen, Boaz H Ng, Joshua D Ooi
Frontiers in Immunology|November 17, 2025
Regulatory T cell therapies: from patient data to biological insightsKameron B Rodrigues, Peter J Eggenhuizen, Rosa Bacchetta, et al.
Plos One|April 8, 2015
FMS-like tyrosine kinase 3 ligand treatment does not ameliorate experimental rapidly progressive glomerulonephritisJoanna R Ghali, Kim M O'Sullivan, Peter J Eggenhuizen, et al.
Nephron|December 13, 2016
Interleukin-17RA Promotes Humoral Responses and Glomerular Injury in Experimental Rapidly Progressive GlomerulonephritisJoanna R Ghali, Kim M O'Sullivan, Peter J Eggenhuizen, et al.
International Journal of Molecular Sciences|March 14, 2026
Are All Cells Created Equal? Novel Cell-Based Regenerative Therapies in Inflammatory Bowel DiseaseAdam R Peterson, Peter J Eggenhuizen, Poh-Yi Gan, et al.
Clinical and Experimental Rheumatology|April 3, 2026
Risk factors for severe infections during induction therapy of patients with microscopic polyangiitisFangling Yao, Yangmei Xie, Jie Li, et al.
Kidney International|May 30, 2014
FcγRIIB regulates T-cell autoreactivity, ANCA production, and neutrophil activation to suppress anti-myeloperoxidase glomerulonephritisJoshua D Ooi, Poh-Yi Gan, Tong Chen, et al.
Frontiers in Medicine|February 4, 2022
Patient Survival Between Hemodialysis and Peritoneal Dialysis Among End-Stage Renal Disease Patients Secondary to Myeloperoxidase-ANCA-Associated VasculitisXueqin Wu, Yong Zhong, Ting Meng, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Biomedicines|March 28, 2024
The Influence of Cross-Reactive T Cells in COVID-19Peter J Eggenhuizen, Joshua D Ooi
Immunology and Cell Biology|December 5, 2020
Antigen-driven CD4<sup>+</sup> T-cell anergy: a pathway to peripheral T regulatory cellsPeter J Eggenhuizen, Boaz H Ng, Joshua D Ooi
International Journal of Molecular Sciences|September 26, 2020
Treg Enhancing Therapies to Treat Autoimmune DiseasesPeter J Eggenhuizen, Boaz H Ng, Joshua D Ooi
Frontiers in Immunology|November 17, 2025
Regulatory T cell therapies: from patient data to biological insightsKameron B Rodrigues, Peter J Eggenhuizen, Rosa Bacchetta, et al.
Plos One|April 8, 2015
FMS-like tyrosine kinase 3 ligand treatment does not ameliorate experimental rapidly progressive glomerulonephritisJoanna R Ghali, Kim M O'Sullivan, Peter J Eggenhuizen, et al.
Nephron|December 13, 2016
Interleukin-17RA Promotes Humoral Responses and Glomerular Injury in Experimental Rapidly Progressive GlomerulonephritisJoanna R Ghali, Kim M O'Sullivan, Peter J Eggenhuizen, et al.
International Journal of Molecular Sciences|March 14, 2026
Are All Cells Created Equal? Novel Cell-Based Regenerative Therapies in Inflammatory Bowel DiseaseAdam R Peterson, Peter J Eggenhuizen, Poh-Yi Gan, et al.
Clinical and Experimental Rheumatology|April 3, 2026
Risk factors for severe infections during induction therapy of patients with microscopic polyangiitisFangling Yao, Yangmei Xie, Jie Li, et al.
Kidney International|May 30, 2014
FcγRIIB regulates T-cell autoreactivity, ANCA production, and neutrophil activation to suppress anti-myeloperoxidase glomerulonephritisJoshua D Ooi, Poh-Yi Gan, Tong Chen, et al.
Frontiers in Medicine|February 4, 2022
Patient Survival Between Hemodialysis and Peritoneal Dialysis Among End-Stage Renal Disease Patients Secondary to Myeloperoxidase-ANCA-Associated VasculitisXueqin Wu, Yong Zhong, Ting Meng, et al.
Pageof 4